Owkin Inc - Company Profile
Powered by 
All the data and insights you need on Owkin Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Owkin Inc Strategy Report
- Understand Owkin Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Owkin Inc (Owkin) is a life science technology company that offers artificial intelligence and machine learning solutions for developing medicines, discovering new treatments, drugs and disease remedies. The company’s services include biomarker engine, drug discovery, clinical development and diagnostics. It develops federated learning solutions for medical research activities. The company utilizes MSIntuit CRC, a CE-marked artificial intelligence (AI) diagnostic, that optimizes microsatellite instability (MSI) testing for colorectal cancer and and RlapsRisk BC that helps in the treatment for early breast cancer patients. It serves in biotechnology, medical research, pharmaceutical and other related industries. Owkin is headquartered in New York City, New York, the US.
Headquarters
United States of America
Address
Unit 3R, 831 Broadway, New York City, 10003
Website
www.owkin.com
No of Employees
350
Industry
Pharmaceuticals and Healthcare
Products and Services
| Services | Brands |
|---|---|
| Biomarker Engine | MSIntuit |
| Drug Discovery | RlapsRisk |
| Clinical Development | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In December, the company and Merck & Co Inc signed a collaboration agreement to develop and market AI-powered digital pathology diagnostics for the EU market. |
| 2023 | Contracts/Agreements | In September, the company entered into a partnership with Tribun Health to advance the development and global deployment of Artificial Intelligence (AI) Diagnostic and Research solutions for pathology departments and pharma companies. |
| 2023 | Contracts/Agreements | The company announced a collaboration with Sectra to expand AI diagnostic for colorectal cancer. |
Competitor Comparison
| Key Parameters | Owkin Inc | Mirum Pharmaceuticals Inc | Allerin Tech Pvt Ltd | Genfit Corp | Madrigal Pharmaceuticals Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | New York City | Foster City | - | Cambridge | West Conshohocken |
| State/Province | New York | California | - | Massachusetts | Pennsylvania |
| No. of Employees | 350 | 264 | - | - | 376 |
| Entity Type | Private | Public | Private | Private | Public |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Jean Jacques Bienaime | Chairman | Executive Board | 2024 | - |
| Thomas Clozel, MD | Director; Chief Executive Officer | Executive Board | - | - |
| Andreas Emmenegger | Chief Financial Officer | Senior Management | 2023 | - |
| Alban de La Sabliere | Chief Operating Officer | Senior Management | - | - |
| Hubert Chaperon | Chief Strategy Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer